{
    "clinical_study": {
        "@rank": "23541", 
        "acronym": "REFLECT", 
        "arm_group": [
            {
                "arm_group_label": "Group A (Tacrolimus Elimination Arm)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Group B (Tacrolimus Minimization Arm)", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is, starting from the Italian clinical practice in liver\n      transplantation, to optimize the immunosuppressive therapy, considering specific patient\n      characteristics as alcoholic cirrhosis, hepatitis C virus (HCV), hepatocellular carcinoma\n      (HCC), and short/long-term implications. Then efficacy and safety of a calcineurin inhibitor\n      (CNI)-withdrawal regimen will be evaluated in comparison with a CNI-minimization regimen."
        }, 
        "brief_title": "REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Transplantation", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria at Baseline:\n\n          -  Male and female liver transplant recipients who are \u2265 18 years of age, treated with a\n             tacrolimus-based immunosuppressive regimen, who have received an induction therapy or\n             i.v. steroids as per local clinical practice.\n\n          -  Recipients of a full-size or technically modified liver allograft will be eligible at\n             4 weeks (\u00b1 7 days) after liver transplantation.\n\n          -  Allograft is functioning at an acceptable level by the time of Baseline as defined by\n             the AST, ALT, total bilirubin levels \u2264 3 times ULN and INR < 1.5 times ULN.\n\n          -  Abbreviated MDRD-4 eGFR \u2265 30 mL/min/1.73m2. Serum creatinine results obtained within\n             5 days prior to Baseline are acceptable.\n\n        Inclusion criteria at Randomization:\n\n          -  Effective tacrolimus minimization, confirmed by stable blood trough levels in the two\n             months prior to randomization, i.e. verification of last two tacrolimus blood trough\n             level \u2264 5 ng/mL in the two months prior to randomization. Investigators should make\n             adjustments in tacrolimus dosing to continue to target trough levels \u2264 5 ng/mL prior\n             to randomization.\n\n          -  Abbreviated MDRD-4 eGFR \u2265 30 mL/min/1.73m2. Serum creatinine results obtained within\n             5 days prior to Visit 5 are acceptable.\n\n        Exclusion criteria at Baseline:\n\n          -  Patients who are recipients of multiple solid organ transplants, (e.g., multivisceral\n             or combined liver-kidney transplants), or have previously received an organ or tissue\n             transplanted, or who received an AB0 incompatible transplant.\n\n          -  Patients who experienced more than one episode of treated biopsy proven acute\n             rejection (BANFF \u2265 3 or RAI \u2265 7) or one steroid-resistant acute rejection.\n\n          -  Patients who require renal replacement therapy.\n\n          -  Patients with a confirmed spot urine protein/creatinine ratio that indicates \u22651.0\n             g/24 hrs of proteinuria.\n\n          -  History of malignancy of any organ system within the past 5 years whether or not\n             there is evidence of local recurrence or metastases, other than non-metastatic basal\n             or squamous cell carcinoma of the skin or HCC.\n\n        Exclusion criteria at Randomization:\n\n          -  Patients who experienced more than two episodes of treated biopsy proven acute\n             rejection (BANFF \u2265 3 or RAI \u2265 7) since transplantation or one steroid-resistant acute\n             rejection during the run-in period.\n\n          -  Patients with a confirmed spot urine protein/creatinine ratio that indicates \u2265 3.0\n             g/24 hrs of proteinuria."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "415", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02115113", 
            "org_study_id": "CRAD001HIT34", 
            "secondary_id": "2013-004325-91"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A (Tacrolimus Elimination Arm)", 
                "description": "Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.\nAt 5 months after transplant, doses will be adjusted to achieve C-0h blood trough level target ranges 6-10 ng/mL.\nTacrolimus withdrawal should be completed by 6 months after transplant.", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group B (Tacrolimus Minimization Arm)", 
                "description": "Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration. At 5 months after transplant, doses will continue to be adjusted to achieve C-0h blood trough level target ranges 3-8 ng/mL.", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group B (Tacrolimus Minimization Arm)", 
                "description": "Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration. At 5 months after transplant, doses will continue to be adjusted to achieve C-0h blood trough level target ranges 3-5 ng/mL.", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Liver transplantation, everolimus, CNI-minimization, CNI-elimination, renal function", 
        "lastchanged_date": "April 11, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ancona", 
                        "country": "Italy", 
                        "state": "AN", 
                        "zip": "60126"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bari", 
                        "country": "Italy", 
                        "state": "BA", 
                        "zip": "70124"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergamo", 
                        "country": "Italy", 
                        "state": "BG", 
                        "zip": "24128"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "state": "BO", 
                        "zip": "40138"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cagliari", 
                        "country": "Italy", 
                        "state": "CA", 
                        "zip": "09134"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cagliari", 
                        "country": "Italy", 
                        "state": "CA", 
                        "zip": "09134"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20162"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20122"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Modena", 
                        "country": "Italy", 
                        "state": "MO", 
                        "zip": "41100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "PD", 
                        "zip": "35128"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pisa", 
                        "country": "Italy", 
                        "state": "PI", 
                        "zip": "56124"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM", 
                        "zip": "00161"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM", 
                        "zip": "00144"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM", 
                        "zip": "00168"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM", 
                        "zip": "00152"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Udine", 
                        "country": "Italy", 
                        "state": "UD", 
                        "zip": "33100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Verona", 
                        "country": "Italy", 
                        "state": "VR", 
                        "zip": "37126"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy", 
                        "zip": "80132"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multicenter, Prospective, Open-label, Controlled, Randomized, Parallel Groups Study to Evaluate the Renal Function of Adult Liver Transplant Recipients Treated With Two Everolimus-based Immunosuppressive Regimens (Tacrolimus Withdrawal vs. Minimization) Until 12 Months Post-transplant, With a 6-months Follow-up", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: The Italian Medicines Agency", 
                "Italy: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Renal function assessed by estimated glomerular filtartion rate (eGFR) using the MDRD-4 formula (Modification of Diet in Renal Disease, 4 variables)", 
            "safety_issue": "Yes", 
            "time_frame": "At 12 months post-transplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02115113"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Composite efficacy failure rate of treated biopsy proven acute rejection (tBPAR), Graft Loss (GL) or Death (D)", 
            "safety_issue": "No", 
            "time_frame": "At 12 months post-transplant"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}